Dr. Glaivy Batsuli, MD is an Assistant Professor of Pediatrics at Stanford University in the Division of Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine. She is a practicing Pediatric Hematologist with the Bass Center for Childhood Cancer and Blood Diseases at Lucile Packard Children’s Hospital. Dr. Batsuli received her B.S. in Public Health at the University of North Carolina at Chapel Hill and her M.D. from the University of Pittsburgh School of Medicine in Pittsburgh, PA. Dr. Batsuli then completed her pediatrics residency and pediatric hematology & oncology fellowship training at Emory University in Atlanta, GA. During fellowship training, she trained in the lab of Dr. Pete Lollar (co-mentored by Dr. Shannon Meeks) where she studied the role of the C1 domain of coagulation protein factor VIII in antibody development using murine models of hemophilia A and pediatric patient samples. In 2016, Dr. Batsuli stayed on the faculty at Emory University in the Department of Pediatrics. In 2023, she joined the faculty at Stanford University where her lab focuses on elucidating mechanisms of the immune response to factor replacement therapies in inherited bleeding disorders in order to develop strategies and therapeutics for antibody prevention and tolerance induction. As a clinician, Dr. Batsuli sees pediatric patients with classical hematologic disorders with expertise in bleeding and clotting disorders.

Hemophilia is a rare inherited X-linked bleeding disorder characterized by the deficiency of blood clotting proteins factor VIII or factor IX. These individuals are at risk for spontaneous bleeds and trauma or surgery-induced bleeding. There have been remarkable advancements in the management of hemophilia to prevent these bleeding episodes and improve quality of life. However, the presence of neutralizing antibodies, called inhibitors, still dictates access to novel therapies such as factor replacement for bleed management and now FDA-approved gene therapies. The Batsuli Lab is focused on elucidating mechanisms of the immune response to blood coagulation proteins in bleeding disorders in order to develop strategies and therapeutics for inhibitor prevention and tolerance induction.

Dr. Batsuli's clinical research interests also include clinical trial participation for novel therapeutics & interventions in bleeding disorders such as hemophilia and von Willebrand disease in addition to coagulation issues & outcomes in ultra-rare bleeding disorders and sickle cell disease.